← Back to Search

Shower Technique Protocol (STP) for Kidney Disease (HIPPO-SAT Trial)

N/A
Waitlist Available
Led By Charmaine Lok, MD, MSc
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 3 and 6 months
Awards & highlights

HIPPO-SAT Trial Summary

Background: The investigators developed a Shower Technique protocol (STP) for hemodialysis (HD) patients with healed central venous catheter (CVC) exit sites, designed to permit showering but not increase infection risk. Research question: Is it feasible to conduct a randomized control trial comparing the rate of CVC related bacteremia (CRB) in adult satellite HD patients using STP versus standard CVC care alone with 6 month follow up? Study Design: This pilot study is a multi-centre randomized control trial. Eligible participants will be randomized to STP versus standard care after meeting predefined criteria to confirm healed tunneled CVC exit site. Primary Outcome: Feasibility will be determined based on 5 outcome measures: accuracy of the CRB rate documentation in the satellite setting, percentage of patients screened, recruited, educated successfully in the STP (intervention arm), and aspects of STP (% of contaminated patients in the control arm). Study Setting: In satellite units affiliated with 2 academic and 3 community centres in south central Ontario, Canada. Patient Population: Adult satellite HD patients dialyzing via CVC with healed CVC exit sites. Intervention: STP and standard CVC care; or Control: standard CVC care; Analysis: Each measure of feasibility has its statistical threshold for success. If the threshold is reached in 4 of the 5 measures, the full HIPPO SAT study will be deemed feasible. Discussion: A pilot feasibility study of the larger study is critical due to the potential challenges associated with recruitment, compliance and contamination.

Eligible Conditions
  • Kidney Disease

HIPPO-SAT Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 3 and 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 3 and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Primary Feasibility Measure of the HIPPO SAT trial: Defined by 5 outcomes
Secondary outcome measures
Secondary Feasibility Outcome: The change in Vascular Access Questionnaire (VAQ) score over time using the Shower Technique protocol compared to standard care.
Secondary Feasibility Outcome: The level agreement between the Deep Breath and CVC Seal tests and the blinded photo test
Other outcome measures
Primary Clinical Outcome Measure: The number of confirmed catheter related bacteremia per 1,000 access days
Secondary Clinical Objective: The mean cost per patient of using the Shower Technique protocol versus standard care
Secondary Clinical Outcome: Patient satisfaction will be measured by the Vascular Access Questionnaire score
+5 more

HIPPO-SAT Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Shower Technique Protocol (STP)Experimental Treatment2 Interventions
Participants will be given a minimum 30 minute personalized educational session by the study coordinator. They will be taught safe and clean techniques for showering with their CVC. If the participant passes the Shower Technique Test, they will be provided a pamphlet on the STP, not to be shared with other participants, to be kept as a reference and placed in their bathroom/household. They will also be given the necessary supplies for the STP.
Group II: Standard CVC careActive Control1 Intervention
Standard CVC Care consists of cleansing with chlorhexidine 2% or povidone (if allergic to chlorhexidine) at the CVC exit site by trained HD nurses followed by placement of a dry gauze dressing by the HD nurse 1x/week or when clinically indicated. In order to participate in the standard CVC care arm, participating sites must have in their policy that it is trained HD nurses who will apply the Polysporin Triple Ointment after standard cleansing with chlorhexidine 2% or povidone during HD, according to guideline recommendations or as per hospital patient care standards and nursing regulations.

Find a Location

Who is running the clinical trial?

London Health Sciences CentreOTHER
143 Previous Clinical Trials
49,880 Total Patients Enrolled
York Central Hospital, OntarioOTHER
2 Previous Clinical Trials
5,052 Total Patients Enrolled
Trillium Health CentreOTHER
7 Previous Clinical Trials
5,006 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~6 spots leftby May 2025